- Home
- GXAI vs CMND Comparison
GXAI vs CMND Comparison
Compare GXAI & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GXAI | CMND |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 5.3M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | GXAI | CMND |
|---|---|---|
| Price | $1.09 | $2.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 88.7K | ★ 639.3K |
| Earning Date | 11-13-2025 | 01-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $694,278.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23205.74 | N/A |
| 52 Week Low | $1.00 | $2.36 |
| 52 Week High | $4.41 | $87.20 |
Technical Indicators
Market Signals| Indicator | GXAI | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 32.96 | 88.83 |
| Support Level | $1.07 | $2.36 |
| Resistance Level | $1.30 | $3.25 |
| Average True Range (ATR) | 0.07 | 0.11 |
| MACD | -0.00 | 0.33 |
| Stochastic Oscillator | 1.79 | 85.86 |
Price Performance
Historical ComparisonAbout GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.